DEF 14A: Ensysce Biosciences Seeks Stockholder Approval for Share Issuance, Reverse Stock Split at Upcoming Annual Meeting

Ensysce Biosciences is holding a virtual annual meeting on November 21, 2024, to vote on proposals including share issuance approval, a reverse stock split, director elections, and auditor ratification.

Summary

• Ensysce Biosciences is convening an annual meeting of stockholders on November 21, 2024, to vote on several key proposals.
• Proposal 1 seeks approval for the full issuance of shares and exercise of warrants to certain investors to comply with Nasdaq Listing Rule 5635(d).
• Proposal 2 involves an amendment to the Certificate of Incorporation to authorize a reverse stock split at a ratio between one-for-ten and one-for-forty, to be determined by the Board.
• Proposal 3 is to elect three Class III directors to serve until the 2027 annual meeting.
• Proposal 4 is to ratify the appointment of Moss Adams LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2024.
• Proposal 5 concerns the potential adjournment of the Annual Meeting to solicit additional proxies.
• The Board of Directors recommends voting FOR all proposals.

Sentiment

Score: 6

Explanation: The document is neutral in tone, primarily providing information about the upcoming annual meeting and proposals. The need for a reverse stock split and potential dilution are concerning, but the company is taking steps to address these issues.

Positives

• Approval of Proposal 1 would allow the company to fully utilize previously secured financing.
• A reverse stock split, if approved, could help the company maintain its Nasdaq listing and improve its stock's appeal to investors.
• The election of directors ensures continuity and oversight of the company's strategic direction.
• Ratifying the auditor provides confidence in the company's financial reporting.

Negatives

• The reverse stock split could be perceived negatively by some investors.
• If Proposal 1 is not approved, the company may be required to hold frequent meetings to seek stockholder approval for warrant exercises.
• The potential issuance of a large number of shares could dilute existing stockholders' ownership.

Risks

• Failure to approve the share issuance could limit the company's ability to fully utilize its financing agreements.
• The reverse stock split may not result in a sustained increase in the stock price.
• Delisting from Nasdaq could negatively impact the company's stock liquidity and investor confidence.
• The company has undertaken reverse stock splits in the past and has been unable to keep the stock price from falling lower.

Future Outlook

The company intends to use the net proceeds from the offerings for continued development of its TAAP and MPAR programs and for working capital.

Management Comments

• The Board of Directors recommends that stockholders vote FOR each of Proposal 1, Proposal 2, Proposal 3, Proposal 4 and the Additional Solicitation Proposal.
• The Board of Directors reasons for seeking approval of each of the proposals are set forth in the attached Proxy Statement.

Industry Context

The company is seeking to maintain its Nasdaq listing, which is a common concern for companies in the biopharmaceutical industry, especially those in the development stage.

Comparison to Industry Standards

• Reverse stock splits are a common strategy employed by companies facing delisting from exchanges like Nasdaq; however, their effectiveness varies.
• Other companies in similar situations, such as Agenus Inc. and Cellectar Biosciences, have also implemented reverse stock splits to regain compliance with minimum bid price requirements.
• The potential dilution from warrant exercises is a typical concern in financings for small-cap biotech companies, requiring careful consideration of the long-term impact on shareholders.

Related Party Transactions

• Ensysce owns 79.2% of EBIR, with the remaining shares owned by affiliates, including the CEO.
• Bob Gower, the Chairman, purchased convertible notes and warrants in a private offering.
• The spouse of Jeff Millard, an executive officer, is also employed by the company.

Stakeholder Impact

• Shareholders will be impacted by the potential dilution from share issuance and the reverse stock split.
• Employees' jobs could be affected by the company's financial stability and ability to fund operations.
• Customers and partners may be impacted by the company's ability to continue developing and commercializing its products.

Next Steps

• Stockholders need to vote on the proposals outlined in the proxy statement.
• The Board will determine the specific ratio for the reverse stock split if approved.
• The company will proceed with the share issuance and warrant exercises if Proposal 1 is approved.

Key Dates

Keywords

Annual Meeting, Proxy Statement, Reverse Stock Split, Share Issuance, Director Election, Auditor Ratification, Nasdaq Listing, Ensysce Biosciences